Metir PLC ($MET.L): The ‘Razor & Blade’ model just got de-risked

Today’s RNS is yet another major step forward by Metir. While the market has been punishing Metir for administrative delays and an overdue AIM audit, the RNS on the Qatar project means the fundamental Free Cash Flow (FCF) inflection Wizard predicted would happen by the end of the year has now been locked in.

Here’s a brief summary of the update and what it means for the shareholders:

• Written 10-Year Commitment: Qatar’s state utility (Kahramaa) formally confirmed a decade-long commitment to Metir’s Continuous Toxicity Monitoring (CTM) tech.

• Phase 1 Handover Locked (Oct 2026): Resolving this milestone unlocks an immediate £205k cash injection (£161k milestone + £44k bonus).

• The Tech works perfectly: The 27 installed hardware units have ‘no material instrument problems.’ The delay was purely logistical - the bio-reagents were degrading in the extreme Middle East heat during shipping. Wait for the unintended super news from this glitch…

• The Fix is a Moat: Metir is sending a specialist biochemist and establishing a local Doha laboratory to produce reagents on-site, permanently fixing the logistics bottleneck.

What This Means (The Thesis)

• The Razor & Blade is Live: The hardware (‘razors’) is installed. Starting in October, the 27 units enter the maintenance phase, locking in ~£30k/month in high-margin 30-day consumable reagent sales (‘the blades’). Recall that Metir makes most of its money from the reagents.

• Phase 2 Upside: The RNS confirms intent to tender 17 more units. If won, that pushes recurring reagent revenue past £50,000 per month (£600k annualized).

• FCF Inflection Unlocked: Establishing local manufacturing embeds Metir permanently into Qatari state infrastructure - virtually impossible for competitors to displace. This is the unintended benefit from the glitch. Fantastic news!

The Bottom Line: The underlying asset is now fundamentally de-risking. An annuity stream of £360k-£600k/year from a single sovereign customer is about to switch on in Q4.

The fund raise we noted previously is still very much on the cards, as management telegraphed in their July 7 accounts (we’re expecting c. £500k-£1m).

Also note that the £205k Qatar milestone payment does not drop until October, and building out the local Doha laboratory to fix the reagent supply chain requires upfront CapEx. So we can expect a placing in the near term to bridge this gap.

However what we now know for sure is that this is growth capital to service a known, 10-year sovereign annuity stream, not desperate rescue capital just to keep the lights on. This will be a ‘good’ fund-raise, ie a fund-raise for liftoff not to extend the company’s cash runway.

So in all a super update from CEO Bob Moore who continues to work miracles on a shoestring budget. Shareholders can be proud of how well he is managing the company’s ‘growing pains’ which we referred to in our last Note - look out for ‘Manager of the Month’ kudos for him in our next Winners and Sinners portfolio review.

More generally, the orders and expansion validate both the value and viability of Microtox. This is the main takeaway from today’s RNS.

In Metir we now have the chrysalis of a company that can go very far indeed.

I picked up some more shares today.